Your browser is no longer supported. Please, upgrade your browser.
AZN [NASD]
AstraZeneca PLC
Index- P/E38.86 EPS (ttm)1.51 Insider Own0.50% Shs Outstand2.62B Perf Week4.18%
Market Cap153.47B Forward P/E15.78 EPS next Y3.72 Insider Trans0.00% Shs Float2.60B Perf Month6.74%
Income3.98B PEG2.10 EPS next Q0.48 Inst Own16.70% Short Float5.08% Perf Quarter20.48%
Sales27.58B P/S5.56 EPS this Y137.20% Inst Trans6.25% Short Ratio15.46 Perf Half Y9.04%
Book/sh5.50 P/B10.68 EPS next Y31.55% ROA6.20% Target Price63.60 Perf Year14.16%
Cash/sh2.97 P/C19.76 EPS next 5Y18.50% ROE29.20% 52W Range46.48 - 64.94 Perf YTD17.54%
Dividend1.40 P/FCF78.46 EPS past 5Y1.70% ROI12.20% 52W High-9.62% Beta0.57
Dividend %2.38% Quick Ratio0.70 Sales past 5Y1.50% Gross Margin79.00% 52W Low26.28% ATR0.77
Employees76100 Current Ratio0.90 Sales Q/Q15.20% Oper. Margin21.20% RSI (14)71.43 Volatility1.35% 1.09%
OptionableYes Debt/Eq1.40 EPS Q/Q99.20% Profit Margin14.40% Rel Volume0.60 Prev Close58.76
ShortableYes LT Debt/Eq1.24 EarningsApr 30 BMO Payout90.40% Avg Volume8.54M Price58.69
Recom1.50 SMA203.00% SMA508.68% SMA20011.53% Volume3,971,559 Change-0.11%
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Jun-15-21 10:54AM  
09:57AM  
08:59AM  
08:21AM  
06:51AM  
06:11AM  
04:38AM  
02:27AM  
Jun-14-21 08:00PM  
08:00PM  
03:19PM  
01:47PM  
01:00PM  
11:45AM  
10:23AM  
07:00AM  
Jun-13-21 09:29AM  
06:37AM  
Jun-11-21 11:11AM  
07:23AM  
07:19AM  
04:51AM  
Jun-10-21 08:00PM  
04:49PM  
01:35PM  
10:34AM  
Jun-09-21 08:00PM  
05:20PM  
04:52PM  
02:53PM  
02:50PM  
03:43AM  
Jun-08-21 08:00PM  
02:03PM  
09:30AM  
Jun-07-21 01:45PM  
12:37PM  
11:50AM  
08:28AM  
07:00AM  
06:25AM  
04:43AM  
01:05AM  
Jun-06-21 09:31AM  
Jun-05-21 08:00PM  
11:02AM  
Jun-04-21 05:50PM  
02:58PM  
02:50PM  
02:34PM  
02:12PM  
11:20AM  
07:32AM  
07:24AM  
07:00AM  
04:54AM  
02:24AM  
02:08AM  
Jun-03-21 10:32PM  
09:31PM  
08:00PM  
08:00PM  
05:40PM  
05:24PM  
05:00PM  
03:32PM  
01:36PM  
11:30AM  
11:02AM  
08:33AM  
Jun-02-21 08:00PM  
05:30PM  
02:15PM  
07:27AM  
07:18AM  
01:44AM  
Jun-01-21 05:30PM  
04:00PM  
02:57PM  
02:40PM  
12:15PM  
09:10AM  
06:38AM  
06:14AM  
May-31-21 08:00PM  
May-30-21 09:19AM  
May-29-21 10:31PM  
May-28-21 05:21PM  
04:11PM  
01:43PM  
12:57PM  
11:40AM  
11:37AM  
08:43AM  
08:07AM  
07:10AM  
07:03AM  
04:34AM  
May-27-21 08:00PM  
04:58PM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.